Story · Medicine & Biotech

Sorafenib Maintenance After Allo-SCT in FLT3-Mutated AML: Long-Term Survival Outcomes From a German Registry

1 outlet · first reported by OncoDaily 3d ago

Coverage, in order

  1. 3d ago
    OncoDaily obscure randomized trial
    Sorafenib Maintenance After Allo-SCT in FLT3-Mutated AML: Long-Term Survival Outcomes From a German Registry

    FLT3 inhibitor maintenance after allogeneic hematopoietic stem cell transplantation (allo-SCT) is supported by randomized data, mainly for sorafenib, from trial settings with uniform selection, timing, and duration. Routine practice varies

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.